CN107921021A - 结晶化合物 - Google Patents

结晶化合物 Download PDF

Info

Publication number
CN107921021A
CN107921021A CN201680035027.1A CN201680035027A CN107921021A CN 107921021 A CN107921021 A CN 107921021A CN 201680035027 A CN201680035027 A CN 201680035027A CN 107921021 A CN107921021 A CN 107921021A
Authority
CN
China
Prior art keywords
crystalline form
xrpd
exhibits
radiation
formulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680035027.1A
Other languages
English (en)
Chinese (zh)
Inventor
A.A.麦金尼
F.拜马斯特
W.皮斯科斯基
F.J.弗雷茨
杨咏来
D.A.恩格斯
V.斯莫伦斯卡亚
V.库苏昆特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka America Pharmaceutical Inc
Original Assignee
Otsuka America Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical Inc filed Critical Otsuka America Pharmaceutical Inc
Priority to CN202310848120.6A priority Critical patent/CN117088802A/zh
Priority to CN202310843667.7A priority patent/CN117466800A/zh
Publication of CN107921021A publication Critical patent/CN107921021A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CN201680035027.1A 2015-06-17 2016-06-17 结晶化合物 Pending CN107921021A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310848120.6A CN117088802A (zh) 2015-06-17 2016-06-17 结晶化合物
CN202310843667.7A CN117466800A (zh) 2015-06-17 2016-06-17 结晶化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181174P 2015-06-17 2015-06-17
US62/181174 2015-06-17
PCT/US2016/038256 WO2016205762A1 (en) 2015-06-17 2016-06-17 Crystalline compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202310843667.7A Division CN117466800A (zh) 2015-06-17 2016-06-17 结晶化合物
CN202310848120.6A Division CN117088802A (zh) 2015-06-17 2016-06-17 结晶化合物

Publications (1)

Publication Number Publication Date
CN107921021A true CN107921021A (zh) 2018-04-17

Family

ID=57546597

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310848120.6A Pending CN117088802A (zh) 2015-06-17 2016-06-17 结晶化合物
CN201680035027.1A Pending CN107921021A (zh) 2015-06-17 2016-06-17 结晶化合物
CN202310843667.7A Pending CN117466800A (zh) 2015-06-17 2016-06-17 结晶化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310848120.6A Pending CN117088802A (zh) 2015-06-17 2016-06-17 结晶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310843667.7A Pending CN117466800A (zh) 2015-06-17 2016-06-17 结晶化合物

Country Status (25)

Country Link
US (5) US9708261B2 (enExample)
EP (3) EP4049997A1 (enExample)
JP (4) JP6896651B2 (enExample)
KR (1) KR102593783B1 (enExample)
CN (3) CN117088802A (enExample)
AU (2) AU2016279075C1 (enExample)
CA (2) CA2989431C (enExample)
CY (1) CY1125352T1 (enExample)
DK (1) DK3597189T3 (enExample)
ES (1) ES2922158T3 (enExample)
HK (1) HK1247125A1 (enExample)
HR (1) HRP20220829T1 (enExample)
HU (1) HUE059348T2 (enExample)
LT (1) LT3597189T (enExample)
MX (2) MX387591B (enExample)
MY (1) MY194868A (enExample)
NZ (2) NZ776973A (enExample)
PH (1) PH12017502324A1 (enExample)
PL (1) PL3597189T3 (enExample)
PT (1) PT3597189T (enExample)
SA (1) SA517390552B1 (enExample)
SG (1) SG10201911417PA (enExample)
SI (1) SI3597189T1 (enExample)
TW (1) TWI751998B (enExample)
WO (1) WO2016205762A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
AU2014374259A1 (en) * 2013-12-09 2016-07-21 Neurovance, Inc. Novel compositions
HUE059348T2 (hu) 2015-06-17 2022-11-28 Otsuka America Pharmaceutical Inc Kristályos vegyületek
US11149004B2 (en) 2017-12-11 2021-10-19 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline form of EB-1020, processes for preparation and use thereof
KR20220083740A (ko) 2019-10-16 2022-06-20 오츠카 세이야쿠 가부시키가이샤 센타나파딘의 제조 방법
US20240246914A1 (en) 2021-05-31 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state form of centanafadine hcl and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019271A1 (en) * 2011-07-30 2013-02-07 Neurovance, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315433A (pt) 2002-11-08 2005-08-30 Dov Pharmaceutical Inc Polimorfos de cloridreto de bicifadine
EA010198B1 (ru) 2004-04-19 2008-06-30 Крка, Товарна Здравил, Д.Д., Ново Место Способы получения полиморфной формы i гидросульфата клопидогрела
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
CN101052393A (zh) 2004-08-18 2007-10-10 Dov药物公司 氮杂双环己烷的新型多晶型物
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
US20070082940A1 (en) * 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) * 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
AU2014374259A1 (en) 2013-12-09 2016-07-21 Neurovance, Inc. Novel compositions
HUE059348T2 (hu) 2015-06-17 2022-11-28 Otsuka America Pharmaceutical Inc Kristályos vegyületek

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019271A1 (en) * 2011-07-30 2013-02-07 Neurovance, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Also Published As

Publication number Publication date
NZ776973A (en) 2022-11-25
SG10201911417PA (en) 2020-01-30
PL3597189T3 (pl) 2022-07-25
CY1125352T1 (el) 2025-05-09
AU2016279075C1 (en) 2021-04-01
EP3310352A4 (en) 2019-03-13
AU2016279075A1 (en) 2018-02-01
AU2021200314B2 (en) 2022-08-04
AU2021200314A1 (en) 2021-03-18
US20180194726A1 (en) 2018-07-12
PH12017502324A1 (en) 2018-06-25
HK1247125A1 (zh) 2018-09-21
MY194868A (en) 2022-12-21
JP2025022896A (ja) 2025-02-14
DK3597189T3 (da) 2022-06-27
JP2023071978A (ja) 2023-05-23
CA3200692A1 (en) 2016-12-22
NZ739044A (en) 2022-08-26
HUE059348T2 (hu) 2022-11-28
JP2018517742A (ja) 2018-07-05
US20200039934A1 (en) 2020-02-06
PT3597189T (pt) 2022-07-05
CA2989431A1 (en) 2016-12-22
AU2016279075B2 (en) 2020-10-22
ES2922158T3 (es) 2022-09-09
US9856217B2 (en) 2018-01-02
JP2021138747A (ja) 2021-09-16
KR102593783B1 (ko) 2023-10-25
JP7583851B2 (ja) 2024-11-14
JP7244575B2 (ja) 2023-03-22
TW201800392A (zh) 2018-01-01
US10280141B2 (en) 2019-05-07
US11299458B2 (en) 2022-04-12
JP6896651B2 (ja) 2021-06-30
WO2016205762A1 (en) 2016-12-22
KR20180014830A (ko) 2018-02-09
EP3597189A1 (en) 2020-01-22
RU2018101244A3 (enExample) 2019-12-23
US10800740B2 (en) 2020-10-13
CA2989431C (en) 2023-08-29
MX387591B (es) 2025-03-18
US9708261B2 (en) 2017-07-18
TWI751998B (zh) 2022-01-11
EP3310352A1 (en) 2018-04-25
MX2017016430A (es) 2018-11-09
SA517390552B1 (ar) 2022-04-13
CN117466800A (zh) 2024-01-30
EP4049997A1 (en) 2022-08-31
HRP20220829T1 (hr) 2022-12-23
SI3597189T1 (sl) 2022-08-31
US20160368871A1 (en) 2016-12-22
MX2020009949A (es) 2020-10-16
LT3597189T (lt) 2022-07-11
EP3597189B1 (en) 2022-06-01
US20170334850A1 (en) 2017-11-23
US20210198198A1 (en) 2021-07-01
CN117088802A (zh) 2023-11-21
RU2018101244A (ru) 2019-07-22

Similar Documents

Publication Publication Date Title
CN107921021A (zh) 结晶化合物
CN104736531A (zh) 包含尼洛替尼和所选择的共晶形成剂的多组分结晶体系
JP2018517742A5 (enExample)
US20120122915A1 (en) Crystalline forms of palonosetron hydrochloride
JP6230743B1 (ja) ヘテロシクリデンアセトアミド誘導体の結晶
CN102232070A (zh) (r)-5-((e)-2-(吡咯烷-3-基乙烯基)嘧啶的合成和新的盐形式
WO2018119291A1 (en) Synthetic methods
RU2789672C2 (ru) Кристаллические соединения
HK40077679A (en) Crystalline compounds
HK40020220A (en) Crystalline compounds
HK40020220B (en) Crystalline compounds
CN116425676A (zh) 一种阿立哌唑晶体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180417